Application 211050
- Type
- ANDA
- Sponsor
- E5 PHARMA INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DIAZOXIDE | DIAZOXIDE | SUSPENSION;ORAL | 50MG/ML | No | No |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 13517-100 | Diazoxide | diazoxide | e5 Pharma, LLC | ANDA | Current |
| 13517-100 | Diazoxide | diazoxide | e5 Pharma, LLC | ANDA | Current |
| 13517-100 | Diazoxide | diazoxide | e5 Pharma, LLC | ANDA | Current |
| 13517-100 | Diazoxide | diazoxide | e5 Pharma, LLC | ANDA | Current |
| 13517-100 | Diazoxide | diazoxide | e5 Pharma, LLC | ANDA | Current |
| 80432-057 | Diazoxide Oral Solution | Diazoxide Oral Suspension | TriRx Huntsville Pharmaceutical Services LLC | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 62166 | ORIG | 2020-03-17 |